Developer docs
API playgroundTry for free, no card

Search company profiles

Kardigan

Full company profile

uuid00005uu

Namestring
Kardigan
Legal namestring
Kardigan, Inc.
Websiteurl
kardigan.bio
Company typeenum
Public
Founded yearint
2023
Descriptiontext

Kardigan is a clinical-stage cardiovascular biotechnology company developing three late-stage drug candidates targeting genetic dilated cardiomyopathy (danicamtiv, Phase 2b/3), calcific aortic valve stenosis (ataciguat, Phase 2b), and acute severe hypertension (tonlamarsen, Phase 2b). All three candidates target root causes of cardiovascular disease in indications with no approved therapies, and are in-licensed from MyoKardia/BMS, Sanofi/Mayo Clinic, and Ionis respectively. The company is supported by a proprietary Cardiac Intelligence platform that integrates Prolaio's clinical intelligence technology — acquired in March 2025 — combining FDA-regulated wearable devices, 510(k)-cleared algorithms, and AI-enabled data analytics for patient identification, continuous physiologic monitoring, and optimized clinical trial design.

The company was founded in 2023 by former MyoKardia executives (MyoKardia was acquired by Bristol Myers Squibb for $13.1 billion in 2020), led by CEO Tassos Gianakakos, and is headquartered in South San Francisco with an East Coast office in Princeton. Total capital raised reached approximately $1 billion across a $300 million Series A (January 2025), a $254 million Series B (October 2025), and a $460 million IPO on Nasdaq (June 2026, ticker KARD). IPO proceeds are allocated to fund Phase 3 trials — $80–90 million each for danicamtiv and ataciguat, and $40–50 million for tonlamarsen — with operations funded through 2028.

Kardigan is pre-revenue with no approved products and operates at a loss, reporting a $56.1 million net loss in Q1 2026 and approximately $16 million in monthly cash burn. The future commercial model is planned as traditional pharmaceutical sales through specialty pharmacies and hospital channels targeting cardiologists and cardiovascular specialists upon regulatory approval, with potential functional cures across its three target indications representing a substantial addressable market.

Short descriptiontext

Kardigan is a clinical-stage cardiovascular biotechnology company developing three late-stage drug candidates (danicamtiv, ataciguat, tonlamarsen) targeting genetic dilated cardiomyopathy, calcific aortic valve stenosis, and acute severe hypertension, supported by an AI-enabled Cardiac Intelligence platform.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiovascular drug development, precision cardiovascular medicine, heart failure therapeutics, clinical-stage biotechnology, antisense oligonucleotide therapy
Industry3 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKABAF
Preventive Cardiology & Lipidology
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiovascular Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Upon regulatory approval, the company plans to commercialize its cardiovascular drug candidates through traditional pharmaceutical sales channels, generating revenue from product sales.

medcitynews.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Prolaio
Description

Clinical intelligence platform with integrated medical insights and data analytics for cardiovascular clinical development, including FDA-regulated devices and 510(k)-cleared algorithms.

kardigan.bio
+3 more records
Core offering1 text field

Kardigan is a clinical-stage precision therapeutics company developing three late-stage investigational drug candidates for cardiovascular diseases: danicamtiv for genetic dilated cardiomyopathy (Phase 2b/3), ataciguat for calcific aortic valve stenosis (Phase 2b), and tonlamarsen for acute severe hypertension (Phase 2b). All three programs are in-licensed from MyoKardia/BMS, Sanofi/Mayo Clinic, and Ionis Pharmaceuticals respectively, and target root causes of cardiovascular disease in indications with no approved therapies. Drug development is supported by the proprietary Cardiac Intelligence platform integrating the acquired Prolaio clinical intelligence system with AI-enabled analytics and continuous patient monitoring via FDA-regulated wearable devices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Danicamtiv demonstrated statistically significant improvements in left atrial function index and left ventricular ejection fraction in Phase 2 study for genetic DCM
+2 more records
Product overview1 text field

Kardigan is a clinical-stage precision therapeutics company developing multiple targeted cardiovascular treatments. The company's portfolio consists of three late-stage clinical programs: Danicamtiv (direct myosin activator for genetic dilated cardiomyopathy), Ataciguat (soluble guanylyl cyclase activator for calcific aortic valve stenosis), and Tonlamarsen (antisense oligonucleotide targeting angiotensinogen for acute severe hypertension). These programs are supported by the proprietary Cardiac Intelligence platform, which integrates the acquired Prolaio clinical intelligence platform for AI-enabled data analytics, continuous physiologic monitoring via FDA-regulated devices, and optimized clinical trial design to advance precision cardiovascular medicine.

Product and service3 records
1Danicamtiv
CategoryCardiovascular Therapeutics / Precision Medicine
Description

An investigational direct and selective activator of atrial and ventricular myosin designed to address root causes of genetic dilated cardiomyopathy (DCM) driven by myosin dysfunction in patients with inherited sarcomere variants. Currently advancing through the Phase 2b/3 KINSHIP-DCM clinical trial.

2Ataciguat
CategoryCardiovascular Therapeutics / Precision Medicine
Description

An investigational soluble guanylyl cyclase (sGC) activator targeting cells and pathways underlying valvular calcification in calcific aortic valve stenosis (CAVS). Currently advancing through the Phase 2b KATALYST-AV clinical trial.

3Tonlamarsen
CategoryCardiovascular Therapeutics / Antisense Oligonucleotide Therapy
Description

An investigational antisense oligonucleotide targeting hepatic angiotensinogen for management of blood pressure in patients with acute severe hypertension. Currently advancing through the Phase 2b KARDINAL-ASH clinical trial.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-01
Description

Kardigan acquired Prolaio, a cardiovascular clinical intelligence company, to enhance its heart health platform and accelerate drug development. The acquisition grants Kardigan access to Prolaio's extensive CV data set and advanced analytics.

2Bristol Myers Squibb / MyoKardia
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-01-01
Description

Kardigan in-licensed exclusive worldwide development and commercialization rights to danicamtiv from MyoKardia, which was acquired by Bristol Myers Squibb for $13.1 billion in 2020. The drug was discovered at MyoKardia and further developed by BMS before rights were licensed to Kardigan.

kardigan.bio
Strategic tierCoreTypeTechnology or Integration
Description

Kardigan acquired rights to ataciguat, an investigational soluble guanylyl cyclase activator developed by Sanofi and Mayo Clinic for the treatment of calcific aortic valve stenosis.

Strategic tierCoreTypeTechnology or Integration
Description

Kardigan in-licensed exclusive worldwide development and commercialization rights to tonlamarsen, an antisense oligonucleotide discovered and developed by Ionis Pharmaceuticals for the treatment of acute severe hypertension.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kardigan

Cardiovascular Therapeuticskardigan.bio

Kardigan is a clinical-stage cardiovascular biotechnology company developing three late-stage drug candidates (danicamtiv, ataciguat, tonlamarsen) targeting genetic dilated cardiomyopathy, calcific aortic valve stenosis, and acute severe hypertension, supported by an AI-enabled Cardiac Intelligence platform.

What Kardigan does

Kardigan is a clinical-stage cardiovascular biotechnology company developing three late-stage drug candidates targeting genetic dilated cardiomyopathy (danicamtiv, Phase 2b/3), calcific aortic valve stenosis (ataciguat, Phase 2b), and acute severe hypertension (tonlamarsen, Phase 2b). All three candidates target root causes of cardiovascular disease in indications with no approved therapies, and are in-licensed from MyoKardia/BMS, Sanofi/Mayo Clinic, and Ionis respectively. The company is supported by a proprietary Cardiac Intelligence platform that integrates Prolaio's clinical intelligence technology — acquired in March 2025 — combining FDA-regulated wearable devices, 510(k)-cleared algorithms, and AI-enabled data analytics for patient identification, continuous physiologic monitoring, and optimized clinical trial design.

The company was founded in 2023 by former MyoKardia executives (MyoKardia was acquired by Bristol Myers Squibb for $13.1 billion in 2020), led by CEO Tassos Gianakakos, and is headquartered in South San Francisco with an East Coast office in Princeton. Total capital raised reached approximately $1 billion across a $300 million Series A (January 2025), a $254 million Series B (October 2025), and a $460 million IPO on Nasdaq (June 2026, ticker KARD). IPO proceeds are allocated to fund Phase 3 trials — $80–90 million each for danicamtiv and ataciguat, and $40–50 million for tonlamarsen — with operations funded through 2028.

Kardigan is pre-revenue with no approved products and operates at a loss, reporting a $56.1 million net loss in Q1 2026 and approximately $16 million in monthly cash burn. The future commercial model is planned as traditional pharmaceutical sales through specialty pharmacies and hospital channels targeting cardiologists and cardiovascular specialists upon regulatory approval, with potential functional cures across its three target indications representing a substantial addressable market.

Kardigan firmographics

Firmographics
Name
Kardigan
Legal name
Kardigan, Inc.
Website
https://kardigan.bio
Company type
Public
Founded year
2023
Operating status
Ipo
Headcount range
101–250 employees
Short description
Kardigan is a clinical-stage cardiovascular biotechnology company developing three late-stage drug candidates (danicamtiv, ataciguat, tonlamarsen) targeting genetic dilated cardiomyopathy, calcific aortic valve stenosis, and acute severe hypertension, supported by an AI-enabled Cardiac Intelligence platform.
Ownership category
akta.pro rank

Kardigan industry classification

Industry
Product category
Cardiovascular Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKABAF
Preventive Cardiology & Lipidology

Keywords

  • Cardiovascular drug development
  • Precision cardiovascular medicine
  • Heart failure therapeutics
  • Clinical-stage biotechnology
  • Antisense oligonucleotide therapy

Where Kardigan is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Kardigan business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech company. Upon regulatory approval, the company plans to commercialize its cardiovascular drug candidates through traditional pharmaceutical sales channels, generating revenue from product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Kardigan product offering

Product offering

Core offering

Kardigan is a clinical-stage precision therapeutics company developing three late-stage investigational drug candidates for cardiovascular diseases: danicamtiv for genetic dilated cardiomyopathy (Phase 2b/3), ataciguat for calcific aortic valve stenosis (Phase 2b), and tonlamarsen for acute severe hypertension (Phase 2b). All three programs are in-licensed from MyoKardia/BMS, Sanofi/Mayo Clinic, and Ionis Pharmaceuticals respectively, and target root causes of cardiovascular disease in indications with no approved therapies. Drug development is supported by the proprietary Cardiac Intelligence platform integrating the acquired Prolaio clinical intelligence system with AI-enabled analytics and continuous patient monitoring via FDA-regulated wearable devices.

Product overview

Kardigan is a clinical-stage precision therapeutics company developing multiple targeted cardiovascular treatments. The company's portfolio consists of three late-stage clinical programs: Danicamtiv (direct myosin activator for genetic dilated cardiomyopathy), Ataciguat (soluble guanylyl cyclase activator for calcific aortic valve stenosis), and Tonlamarsen (antisense oligonucleotide targeting angiotensinogen for acute severe hypertension). These programs are supported by the proprietary Cardiac Intelligence platform, which integrates the acquired Prolaio clinical intelligence platform for AI-enabled data analytics, continuous physiologic monitoring via FDA-regulated devices, and optimized clinical trial design to advance precision cardiovascular medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • Prolaio: Clinical intelligence platform with integrated medical insights and data analytics for cardiovascular clinical development, including FDA-regulated devices and 510(k)-cleared algorithms.
  • KINSHIP-DCM
  • KATALYST-AV
  • KARDINAL-ASH

Products and services

  • Danicamtiv An investigational direct and selective activator of atrial and ventricular myosin designed to address root causes of genetic dilated cardiomyopathy (DCM) driven by myosin dysfunction in patients with inherited sarcomere variants. Currently advancing through the Phase 2b/3 KINSHIP-DCM clinical trial.
  • Ataciguat An investigational soluble guanylyl cyclase (sGC) activator targeting cells and pathways underlying valvular calcification in calcific aortic valve stenosis (CAVS). Currently advancing through the Phase 2b KATALYST-AV clinical trial.
  • Tonlamarsen An investigational antisense oligonucleotide targeting hepatic angiotensinogen for management of blood pressure in patients with acute severe hypertension. Currently advancing through the Phase 2b KARDINAL-ASH clinical trial.

Quantifiable outcome

  • Danicamtiv demonstrated statistically significant improvements in left atrial function index and left ventricular ejection fraction in Phase 2 study for genetic DCM
  • +2 more outcomes

Companies that use Kardigan

Customer profile

Segments3 records

Ideal customer profiles2 records

Kardigan technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature2 records

Kardigan partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • ProlaiocoreTechnology or Integration · 1 March 2025Kardigan acquired Prolaio, a cardiovascular clinical intelligence company, to enhance its heart health platform and accelerate drug development. The acquisition grants Kardigan access to Prolaio's extensive CV data set and advanced analytics.
  • Bristol Myers Squibb / MyoKardiacoreTechnology or Integration · 1 January 2020Kardigan in-licensed exclusive worldwide development and commercialization rights to danicamtiv from MyoKardia, which was acquired by Bristol Myers Squibb for $13.1 billion in 2020. The drug was discovered at MyoKardia and further developed by BMS before rights were licensed to Kardigan.
  • Sanofi and Mayo CliniccoreTechnology or IntegrationKardigan acquired rights to ataciguat, an investigational soluble guanylyl cyclase activator developed by Sanofi and Mayo Clinic for the treatment of calcific aortic valve stenosis.
  • Ionis PharmaceuticalscoreTechnology or IntegrationKardigan in-licensed exclusive worldwide development and commercialization rights to tonlamarsen, an antisense oligonucleotide discovered and developed by Ionis Pharmaceuticals for the treatment of acute severe hypertension.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Kardigan competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Kardigan social profiles

Digital presence

Kardigan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kardigan leadership team

Management profile

Number of profiles

Profiles17 records

Kardigan subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Kardigan funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kardigan M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kardigan

What does Kardigan do?

Kardigan is a clinical-stage precision therapeutics company developing three late-stage investigational drug candidates for cardiovascular diseases: danicamtiv for genetic dilated cardiomyopathy (Phase 2b/3), ataciguat for calcific aortic valve stenosis (Phase 2b), and tonlamarsen for acute severe hypertension (Phase 2b). All three programs are in-licensed from MyoKardia/BMS, Sanofi/Mayo Clinic, and Ionis Pharmaceuticals respectively, and target root causes of cardiovascular disease in indications with no approved therapies. Drug development is supported by the proprietary Cardiac Intelligence platform integrating the acquired Prolaio clinical intelligence system with AI-enabled analytics and continuous patient monitoring via FDA-regulated wearable devices.

Is Kardigan a public or private company?

Kardigan is a public company. It is classified as public and is currently ipo.

When was Kardigan founded?

Kardigan was founded in 2023. It employs 101 to 250 people.

Where is Kardigan based?

Kardigan is headquartered in Princeton, United States, in the North America region.

How does Kardigan make money?

One revenue line is on record: pharmaceutical Product Sales.

Does Kardigan have an API?

No public API is recorded for Kardigan.

What industry is Kardigan in?

Kardigan's product category is Cardiovascular Therapeutics. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewLeerink Partners maintains Kardigan at Outperform, lowers price target to $36 from $37Leerink Partners maintained Kardigan at Outperform and lowered its price target to $36 from $37. The target implies a 155% upside from the Nov 12 close of $14.12. Recent analyst price targets range from $42 to $50.Quiver QuantitativeKARDIGAN ($KARD) Releases Q3 2026 Earnings | KARD Stock NewsKARDIGAN reported Q3 2026 earnings of -$0.64 per share, beating estimates of -$0.84, with revenue of $0. Insiders made three purchases in the past six months, and 69 institutional investors added shares while 6 reduced positions in the most recent quarter.MarketScreenerKardigan Q3 Net Loss FallsKardigan reported a Q3 net loss of $0.64 per share, beating the $0.75 loss estimated by FactSet. The stock closed at $15.68, up 3.29% on the day.Business Wire BlogKardigan to Participate in the Jefferies Global Healthcare ConferenceKardigan will participate in a fireside chat at the 2026 Jefferies London Healthcare Conference on November 18 at 4:30 PM GMT. A live webcast will be available on the company's website, with a replay provided for a limited time after the event.FinancialContent Business PageArticles from Kardigan, Inc.Kardigan, a clinical-stage precision therapeutics company, priced its initial public offering of 25 million shares at $16 per share, with gross proceeds expected to be $400 million before underwriting discounts and commissions. The company granted underwriters a 30-day option to purchase up to 3.75 million additional shares at the offering price.Stock TitanKardigan to Join Jefferies London Healthcare ConferenceKardigan will participate in a fireside chat at the Jefferies London Healthcare Conference on November 18, 2026, at 4:30 PM GMT. A live webcast will be available on the company's website, with a replay provided for a limited time after the event.American Banking and Market NewsKardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 ResultsKardigan extended its phase 2 trial of ataciguat for aortic stenosis to assess the primary endpoint at 48 weeks instead of 24, with top-line results expected in the second half of 2027. The company plans an interim analysis at 24 weeks and expects to share phase 3 planning details in the first half of 2027.Seeking AlphaKardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV Baseline Findings TranscriptKardigan's CEO Tassos Gianakakos announced that the KATALYST-AV Phase II study of ataciguat in aortic stenosis is fully enrolled, calling it a foundational milestone. The call also covered aortic stenosis progression data and baseline findings from the study.MarketBeatKardigan Extends Phase 2 Ataciguat Trial Assessment, Targets 2027 ResultsKardigan extended its phase 2 trial of ataciguat in aortic stenosis to a 48-week primary endpoint assessment, with top-line results expected in the second half of 2027. The company will use interim data at 24 weeks to inform phase 3 design, and expects to share more on the registrational trial in the first half of 2027.TradingViewKARD: KATALYST-AV reaches full enrollment; Week 48 data will guide ataciguat’s Phase 3 pathKATALYST-AV completed enrollment, with its primary AVC assessment extended to Week 48 and topline data expected in H2 2027. Real-world findings linking cardiac damage markers and rapid AVA decline with worse outcomes are informing Phase 3 design.